- Home
- KNDI vs SKYE Comparison
KNDI vs SKYE Comparison
Compare KNDI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- SKYE
- Stock Information
- Founded
- KNDI 2002
- SKYE 2012
- Country
- KNDI China
- SKYE United States
- Employees
- KNDI N/A
- SKYE N/A
- Industry
- KNDI Auto Manufacturing
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- KNDI Consumer Discretionary
- SKYE Health Care
- Exchange
- KNDI Nasdaq
- SKYE Nasdaq
- Market Cap
- KNDI 109.2M
- SKYE 108.5M
- IPO Year
- KNDI N/A
- SKYE N/A
- Fundamental
- Price
- KNDI $1.38
- SKYE $3.86
- Analyst Decision
- KNDI
- SKYE Buy
- Analyst Count
- KNDI 0
- SKYE 7
- Target Price
- KNDI N/A
- SKYE $15.50
- AVG Volume (30 Days)
- KNDI 214.1K
- SKYE 316.3K
- Earning Date
- KNDI 08-19-2025
- SKYE 11-06-2025
- Dividend Yield
- KNDI N/A
- SKYE N/A
- EPS Growth
- KNDI N/A
- SKYE N/A
- EPS
- KNDI N/A
- SKYE N/A
- Revenue
- KNDI $104,035,613.00
- SKYE N/A
- Revenue This Year
- KNDI N/A
- SKYE N/A
- Revenue Next Year
- KNDI N/A
- SKYE N/A
- P/E Ratio
- KNDI N/A
- SKYE N/A
- Revenue Growth
- KNDI N/A
- SKYE N/A
- 52 Week Low
- KNDI $0.89
- SKYE $1.14
- 52 Week High
- KNDI $2.07
- SKYE $6.13
- Technical
- Relative Strength Index (RSI)
- KNDI 49.63
- SKYE 52.64
- Support Level
- KNDI $1.34
- SKYE $3.96
- Resistance Level
- KNDI $1.45
- SKYE $4.55
- Average True Range (ATR)
- KNDI 0.07
- SKYE 0.31
- MACD
- KNDI -0.02
- SKYE 0.04
- Stochastic Oscillator
- KNDI 19.05
- SKYE 45.67
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.